Currently interviewing for general cancer imaging fellowship positions beginning July 2021. Also interviewing for 2022-2023.
The Cancer Imaging Program (CIP) Fellowship at Dana-Farber Cancer Institute provides extensive experience in body imaging including MRI, CT, PET/CT, and US in adult patients with cancer. Dana-Farber Cancer Institute (DFCI) is a Harvard Medical School Teaching affiliate and provides adult clinical care jointly with Brigham and Women’s Hospital.
Depending on chosen track (General cancer imaging or PET-CT); 80% time will be spent reading cancer imaging studies with our CT, MR, U/S, or PET-CT.
Approximately 20% of the fellow’s time can be dedicated to research assuming that a detailed research project outline has been presented and approved by an attending radiologist as the project mentor. Research milestone schedules are clearly articulated, and research progress is closely monitored.
Four weeks of the CIP fellowship is designated elective time. Elective time may be spent on approved research projects, or in other radiology disciplines elsewhere.
On-call responsibilities consist of weekend day coverage.
Weekday coverage rotations in the Imaging department at Dana-Farber Boston and Dana-Farber Chestnut Hill.
U.S. applicants must be board-eligible or board-certified in radiology. Foreign applicants must be ECFMG certified and eligible to obtain a clinical visa prior to starting the fellowship. The fellowship at DFCI is structured in accordance with the fellowship regulations as provided by the Department of Radiology at BWH.
Teaching/Conference Responsibilities: There is a weekly seminar series designated for Category 1 CME credit, including introductory and modality-based lectures and disease-centric “blocks” thereafter. Other educational activities include a weekly radiology-pathology conference, drug conferences and MRI/CT case conferences. These are in addition to continual one-on-one teaching throughout the day.
Fellowship Supervision and Evaluation:
DFCI Cancer Imaging Fellows will receive continuous on-site training, teaching and feedback. Dr. Fiona Fennessy, Director of the DFCI Cancer Imaging Fellowship Program, Dr. Fadi El-Merhi, Associate Director of the Fellowship Program, and the Chief of the Department of Imaging, DFCI, will evaluate the fellow’s performance.
Equipment and Resources:
State-of-the-art equipment includes 64-slice CT, 1.5-T and 3-T MRI, PET/CT, digital radiography, Hologic digital tomosynthesis mammography, Philips IU22 ultrasound, GE LOGIQ E9 XDclear 2.0 ultrasound, and gamma camera systems.
Applicants should send C.V., Personal statement, USMLE scores, 3 reference letters (which must be sent directly by the referees) to the address below, and a recent photograph of yourself. Canadian Physicians and Doctors of Osteopathy who are eligible may substitute documents: LMCC/MCCQE and COMLEX examinations. Other foreign applicants must send ECFMG certification.
Fiona M. Fennessy, MD, PhD, Cancer Imaging Fellowship Program Director
Fadi El-Merhi, MD, Cancer Imaging Fellowship Associate Director
Dana-Farber Cancer Institute, Department of Imaging
450 Brookline Ave, Boston MA 02215
Attention: Ashley Watterson, Room DL-198
TEL: (617) 632-4891; FAX: (617) 582-8574
Internal Number: 1234
About Dana-Farber Cancer Institute
Radiology Fellowship Programs
The department offers a variety of fellowship programs for individuals who have completed a residency in radiology. Each fellowship provides clinical training in all types of related examinations and wide opportunities for research supervised by senior staff members engaged in ongoing investigations. The experience is closely coordinated with activities in related clinical and surgical specialties.
The Cancer Imaging Program (CIP) Fellowship at Dana-Farber Cancer Institute provides extensive experience in body imaging, including MRI, CT, PET-CT, and US in adult patients with cancer. Dana-Farber Cancer Institute (DFCI) is a Harvard Medical School Teaching affiliate and provides adult clinical care jointly with Brigham and Women's Hospital (BWH).